Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs ...

Lonza said Wednesday morning it is on the hunt for deals to increase its capacity and technology offerings, which comes after ...

The Trump ad­min­is­tra­tion said on Wednes­day it will con­sid­er “op­por­tu­ni­ties to bring greater trans­paren­cy” to the ...

The first of two confirmation hearings is now underway for Robert F. Kennedy, Jr. to serve as President Donald Trump’s HHS ...

Zentalis Pharmaceuticals is axing about 40% of its staff and doubling down on advancing its only pipeline candidate as part ...

A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer ...

President Donald Trump’s communications and travel freeze at HHS may be part of the reason an upcoming FDA advisory committee ...

FDA expands Ozempic label to include kidney disease benefits in type 2 diabetes patients. Novo Nordisk's drug can now be ...

Curie.Bio reveals $340M seed fund, Cullinan's zipalertinib succeeds in lung cancer trial, Benchling cuts 10% staff, I-Mab reduces workforce, Regulus shares Phase 1b data, Imvax raises $29M ...

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News.

Affini-T Therapeutics appears to have cut staff last week, according to LinkedIn posts from people who say they are or were ...